Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pisetsky’s Rules vs. the Peltzman Effect

David S. Pisetsky, MD, PhD  |  Issue: July 2009  |  July 1, 2009

David S. Pisetsky, MD, PhD

After almost 40 years in medicine, I think that I know a thing or two about drug therapy. I have treated thousands of patients, participated in clinical trials, and run a lab focused on mechanisms that can be targeted for new treatments. My bona fides should therefore be in good shape.

I like to teach and, for pedagogical purposes, have tried to distill this accumulated knowledge into clever and witty bite-sized pieces of information to enlighten and entertain my trainees. In today’s lexicon, these bullets of information would be called “teaching points” or “take-home messages” but, in reality, they are the wisdom of an elder (alas, that’s what 40 years on the job makes you).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Not afraid of self-promotion, I want to name these precepts after myself, although I am undecided whether they should be called Pisetsky’s Rules, Laws, or Maxims. Perhaps Pisetsky’s Rules sets the right tone. At this point, there are many such rules. Here are a few:

  • The best way to reduce the side effects of a drug is not to prescribe it.
  • Drugs come to market underdosed or overdosed. The trouble is that you don’t know which it is.
  • Unless you are treating cancer, watch out for drugs that kill cells.

Of all the rules, the one which I think is the most important (and to which I fervently want my name attached in eternity) is this one: A drug becomes dangerous the moment that you think it is safe. I thought that this rule was original and important and, indeed, if respected and applied, would make the use of drugs more safe and responsible. Imagine my disappointment when I discovered that what I thought was a brand-new insight was well known and already had a name: the Peltzman Effect. Forget Pisetsky’s cardinal rule of drug therapy; Peltzman got there first.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Peltzman Effect

The Peltzman Effect was promulgated by the economist Sam Peltzman after the work of Ralph Nader on car safety, and was a rejoinder to the idea that exposing safety defects would diminish the carnage on the highway. The common-sense notion—indeed, the foundation of Nader’s work—is the proposition that the knowledge that cars can be dangerous would spur engineering advances to boost safety. Think seat belts, airbags, and anti-lock brakes.

Is there any conceivable way that such nifty innovations could fail to make highways less treacherous places? To that question, Peltzman answered that engineering improvements regulated by law could detract from safety because people felt more secure and therefore took more risks on the road, their more rash behavior nullifying safety benefits. If I think that my brakes can stop my car on a dime, I may put the pedal to the metal or drive on slick icy roads as if they were dry pavement. Or, knowing that I am surrounded by a protective cushion of airbags that can poof instantaneously with the slightest jar, I may text a message while cruising down U.S. Interstate 95 at 70 miles an hour.

Page: 1 2 3 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:Drug SafetyMedicationQualityRheumatoid arthritisSafety

Related Articles

    “The Pisetsky Effect”* Helps Mold The Rheumatologist into a Vibrant Publication

    December 12, 2011

    Colleagues and contributors share thoughts as the first editor’s tenure comes to a close

    Rheum After 5: Dr. David Pisetsky, Storyteller

    April 15, 2022

    David S. Pisetsky, MD, PhD, often tells people that science involves reading and writing as much as conducting experiments. No matter what discoveries are made in the lab, if they can’t be communicated well or put into context, he asks, how can they be used to advance the field and benefit patients? The recipient of…

    A 52-Year-Old Lupus Paper Remains Important Today

    December 14, 2020

    Over 50 years ago, an article appeared in The New England Journal of Medicine: “Immunologic Factors and Clinical Activity in Systemic Lupus Erythema­tosus.”1 Written by a young postdoctoral fellow, Peter H. Schur, MD, and colleagues, the article synthesized important work in the field at the time. What follows is a discussion of the historical context…

    The History of The Rheumatologist

    December 8, 2022

    The Rheumatologist (TR) premiered in 2006, with its first full year of publication in 2007. In the 15 years since, it has sought to provide clinicians, researchers and healthcare providers with the most stimulating and educational content found in the field of rheumatology. The responsibility for achieving this mission has been borne by just three…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences